Ascletis Pharma Inc.

Investors

Next Day Disclosure Returns - Others
2021-01-14
Voluntary Announcement - Gannex Announces Positive Phase I Clinical Results on Its THR-beta Agonist ASC41
2021-01-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
2021-01-05
Grant of Share Options
2020-12-31
Voluntary Announcement - First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
2020-12-28
Voluntary Announcement - Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
2020-12-22
Next Day Disclosure Returns - Share Buyback
2020-12-14
Voluntary Announcement - Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42, an FXR Agonist
2020-12-14
Next Day Disclosure Returns - Share Buyback
2020-12-04
Voluntary Announcement - ASC22 (Envafolimab) Is Safe and Well Tolerated in Phase IIa HBV Study and Phase IIb HBV Clinical Trial Has Been Initiated
2020-12-04

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号